Cargando…
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
BACKGROUND: Morning symptoms associated with COPD have a negative impact on patients’ quality of life. Long-acting bronchodilators with rapid onset may relieve patients’ symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator pr...
Autores principales: | Marin, Jose M, Beeh, Kai M, Clemens, Andreas, Castellani, Walter, Schaper, Lennart, Saralaya, Dinesh, Gunstone, Anthony, Casamor, Ricard, Kostikas, Konstantinos, Aalamian-Mattheis, Maryam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934556/ https://www.ncbi.nlm.nih.gov/pubmed/27418815 http://dx.doi.org/10.2147/COPD.S106127 |
Ejemplares similares
-
Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019) -
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
por: Vogelmeier, Claus F., et al.
Publicado: (2017) -
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017) -
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
por: Greulich, Timm, et al.
Publicado: (2018) -
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017)